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Background: Despite a class IIa indication for Digoxin use in
heart failure by both ACC/AHA and ESC, its use has been going
down in the last decade. One of the reasons has been the
result of The Digitalis Investigation Group (DIG) Trial. This
randomized controlled study in 6800 patients of ambulatory
heart failure (age 21 yrs, LV ejection fraction 45%, normal
sinus rhythm) failed to show a mortality benefit from Digoxin
use. It did however demonstrate a reduction in hospitaliza-
tions overall and for worsening heart failure.
Objectives: Since more than half of these heart failure
patients had high risk features characterized by class IIIeIV
symptoms, or ejection fraction lower than 25% or with a CT
ratio more than 55% a subanalysis of DIG Trial data was
planned to see the effect of Digoxin in this subcategory in
terms of the composite endpoints of mortality or hospitali-
zations over 2 years.
Patients and methods: From the dataset of DIG patients
obtained from the National Heart Blood and Lung Institute,
4367 high risk patients (mean age 64 years, 26% females) were
analyzed. There were 2223 (51%) with class IIIeIV symptoms,
2256 (52%) with LVEF<25%, and 2345 (54%) with CTR>55%. All
high risk feature groups were analyzed separately and also
together.
Pearson chi square andWicoxon rank sum tests showed no
significant difference in the baseline characteristics, including
medical history, cause of heart failure and drug use between
the three groups (except that dyspnea was more in the those
with class IIeIV symptoms). Outcomes were assessed using
Kaplan Meier and Cox proportional hazard analyses. Statis-
tical analysis was two tailed in all cases and a p value of <0.05
was considered significant.
Results: Results at 24 months showed that all-cause
mortality or all-cause hospitalization was significantly better
with Digoxin use versus placebo. Hazard ratio for NYHA class
IIIeIV was 0.88 (p ¼ 0.012); 0.84 (p ¼ 0.001) for LVEF <25% and
0.85 (p ¼ 0.002) for those with CTRs >55%, absolute risk
reduction being2%,6% and4% respectively. Therewas an
absolute risk reduction of 3% in favor of Digoxin if any of the
three high risk feature was present (p  0.001). Also, signifi-
cantly less patients receiving Digoxin experienced heart
failure related mortality or hospitalization. HR was 0.65
(p< 0.001) for NYHA class IIIeIV; 0.61 (p< 0.001) for LVEF<25%
and 0.65 (p < 0.001) for CTRs >55%(absolute risk reductionof 11%, 12%, 11%, 10% respectively and 11% when any
of the high risk features were present; p ¼ 0.001).
Conclusion: Digoxin use reduced the primary endpoint of
all-cause and heart failure mortality or hospitalizations in
high risk heart failure patients. This effect was primarily
driven by reduction in hospitalizations with no significant
effect on mortality.
Implications
Heart failure hospitalization is plagued not only by increasing
mortality but also by high rates of repeated admissions
(15e30% within 60e90 days of discharge). This has socioeco-
nomic implications and can be addressed with Digoxin. This
being an inexpensive and relatively safe drug could be used in
those patients where severe signs and symptoms persist after
hospitalization for heart failure.
This above discussed substudy as with the parent DIG trial
did not report mortality benefit. One of the reasons implicated
is a possible increased serum concentrations of Digoxin that
adversely affected the outcomes. Moreover patients in this
trial did not receive either Beta-blockers or Aldosterone
antagonists which affect outcomes and are recommended in
the present HF guidelines. Whether the finding of this trial
that did not have an Asian population can be applied fully in
the Indian context is also an issue. Lastly the question of
Digoxin use in heart failurewith preserved LVEF remains open
for investigation.
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Clinical perspective
The TARGET study attempts to improve outcomes in patients
undergoing cardiac resynchronization therapy (CRT). Identi-
fying the latest site of left ventricular (LV) contraction by
